Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical said Sept. 24 its U.S. R&D subsidiary, Takeda Global Research & Development Center, had applied to the U.S. Food and Drug Administration for approval to market an alogliptin/Actos combination tablet for the treatment of type 2 diabetes